Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Enhanced oxaliplatin-induced apoptosis following antisense Bcl-xl down-regulation is p53 and Bax dependent: Genetic evidence for specificity of the antisense effect.

Molecular cancer therapeutics - 1 Feb 2004

Hayward Richard L, Macpherson Janet S, Cummings Jeff, Monia Brett P, Smyth John F, Jodrell Duncan I

Abstract excerpt

INTRODUCTION: Oxaliplatin, licensed for colorectal cancer chemotherapy, damages DNA by generating intrastrand and interstrand cross-links and can induce apoptosis via a Bax-dependent pathway. Bcl-xl, an antiapoptotic Bcl-2 family member, regulates apoptosis and chemoresistance in several cancer models. Bcl-xl expression correlates with invasiveness in primary colorectal cancer. Bcl-xl may therefore represent a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to bcl-2-Associated X Protein
Share to bcl-X Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cyclin-Dependent Kinase Inhibitor p21

Share to DNA, Antisense

Share to HCT116 Cells

Share to Oligonucleotides, Antisense

Share to Organoplatinum Compounds

Share to Oxaliplatin

Source

Identifiers

PMID: 14985457

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Enhanced oxaliplatin-induced apoptosis following antisense Bcl-xl down-regulation is p53 and Bax dependent: Genetic evidence for specificity of the antisense effect.PMID 14985457Read ↗

Molecular mechanisms of action and prediction of response to oxaliplatin in colorectal cancer cellsSemantic proximity Read ↗

Bcl-xL is a key mediator of apoptosis following KRAS <sup>G12C</sup> inhibition in <i>KRAS</i> <sup> <i>G12C</i> </sup> mutant colorectal cancerSemantic proximity Read ↗

Reversal of Mutant KRAS-Mediated Apoptosis Resistance by Concurrent Noxa/Bik Induction and Bcl-2/Bcl-xL Antagonism in Colon Cancer Cells.Semantic proximity Read ↗

Identification of BCL-XL as highly active survival factor and promising therapeutic target in colorectal cancerSemantic proximity Read ↗

Bcl-xL is an oncogenic driver in colorectal cancer.Semantic proximity Read ↗

CRISPR screens identify a novel combination treatment targeting BCL-XL and WNT signaling for KRAS/BRAF-mutated colorectal cancers.Semantic proximity Read ↗

Role of BAX in the apoptotic response to anticancer agents.Semantic proximity Read ↗

BCL-XL is crucial for progression through the adenoma-to-carcinoma sequence of colorectal cancerSemantic proximity Read ↗

A Novel Combination Treatment Targeting BCL-XL and MCL1 for KRAS/BRAF-mutated and BCL2L1-amplified Colorectal Cancers.Semantic proximity Read ↗

Resistance of colon cancer cells to long-term 5-fluorouracil exposure is correlated to the relative level of Bcl-2 and Bcl-X(L) in addition to Bax and p53 status.Semantic proximity Read ↗

Targeting antioxidant enzymes enhances the therapeutic efficacy of the BCL-XL inhibitor ABT-263 in KRAS-mutant colorectal cancers.Semantic proximity Read ↗

Hypoxia-Mediated Down-Regulation of Bid and Bax in Tumors Occurs via Hypoxia-Inducible Factor 1-Dependent and -Independent Mechanisms and Contributes to Drug ResistanceSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.